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Abstract
Background: Recognizing specific protein changes in response to drug administration in humans has the potential for the
development of personalized medicine. Such changes can be identified by pharmacoproteomics approach based on
proteomic technologies. It can also be helpful in matching a particular target-based therapy to a particular marker in a
subgroup of patients, in addition to the profile of genetic polymorphism. Warfarin is a commonly prescribed oral
anticoagulant in patients with prosthetic valve disease, venous thromboembolism and stroke.
Methods and Finding: We used a combined pharmacogenetics and iTRAQ-coupled LC-MS/MS pharmacoproteomics
approach to analyze plasma protein profiles of 53 patients, and identified significantly upregulated level of transthyretin
precursor in patients receiving low dose of warfarin but not in those on high dose of warfarin. In addition, real-time RT-PCR,
western blotting, human IL-6 ELISA assay were done for the results validation.
Conclusion: This combined pharmacogenomics and pharmacoproteomics approach may be applied for other target-based
therapies, in matching a particular marker in a subgroup of patients, in addition to the profile of genetic polymorphism.
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Introduction
Warfarin is an oral anticoagulant commonly employed in the
treatment and prevention of thromboembolic events such as
myocardial infarction, atrial fibrillation and deep vein thrombosis
[1,2]. However, large inter- and intra-individual variabilities in
treatment responses coupled with a narrow therapeutic range have
made the clinical optimization of warfarin doses difficult. The dose
requirements for warfarin have been shown to be influenced by
various factors including age, weight, ethnicity, vitamin-K
enriched diet, drug interactions and genetics of individuals
[3,4,5,6,7,8]. Current clinical practice utilizes the international
normalization ratio (INR) to optimize the dose of warfarin in
individual patients which has performed far from ideal. The
pharmacogenetics of warfarin has been the focus of recent
research to elucidate the factors which can influence the dose of
warfarin and identify the biomarkers which predict the optimal
warfarin doses [9,10,11].
Warfarin is an orally administered coumarin derivative which is
rapidly absorbed into the systemic circulation with bioavailability
of 100%. Up to 99% of the circulating drug is bound to plasma
albumin and alpha-1-acid glycoprotein. Warfarin is present as a
racemic mixture of S- and R- enantiomers with S-warfarin being 3
to 5 times more active than the R-enantiomer [12,13]. Besides the
activity, the metabolic profiles of the 2 enantiomers have also been
found to differ. The metabolism of S-warfarin to its inactive
metabolite, 7-hydroxywarfarin, is predominantly catalyzed by
CYP2C9 (Cytochrome P450 2C9) with minor contributions from
CYP2C8 and CYP2C19. In contrast, R-warfarin is mainly
metabolized by CYP1A2 and CYP3A4 to form the inactive
metabolites, 8-hydroxywarfain and 10-hydroxywarfain, respec-
tively [12]. Other enzymes which play minor roles in this
metabolic pathway include CYP1A1, CYP2C8, CYP2C9 and
CYP3A5. The impact of CYP2C9 polymorphic variants on the
pharmacokinetics and pharmacodynamics of warfarin has been
extensively studied in patients from different ethnic backgrounds
[14,15,16,17]. In particular, CYP2C9*2 and *3 polymorphisms
have been associated with greater risk of bleeding complications
and lower warfarin dose requirements. Surprisingly, CYP2C9
polymorphisms were only found to account for approximately 7–
10% of the variation in warfarin dose [14,18,19].
Warfarin exerts its anti-coagulant effect by non-competitively
inhibiting the action of vitamin K epoxide reductase complex
subunit 1 (VKORC1) in an allosteric manner. VKORC1 catalyses the
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essential co-factor for c-glutamylcarboxylase (GGCX). GGCX is
an enzyme which catalyses the c-carboxylation of glutamic acid
residues of clotting factors and proteins C, S and Z [20,21]. Lately,
functional genetic variants in the VKORC1 gene have been found
to affect the pharmacodynamics of warfarin and influence its
dosage requirements in patients. Rieder et al., (2005) [22] have
previously identified five haplotypes which are differentiated by
five non-coding single nucleotide polymorphisms. These five
haplotypes were found to segregate the patients into low- and
high- dose groups and account for approximately 25% of the
variability in warfarin doses. In a more recent study in Asian
population, the VKORC1 diplotypes were found to contribute to
approximately 59.1% of the variability in warfarin dose require-
ment. In multivariate analysis, age, weight and genetic polymor-
phisms presenting CYP2C9 and VKORC1 accounted for 74.2% of
the warfarin dose variability [23]. Approximately 25% of the
variations in dose requirements still remained unexplained.
Although the availability of high-throughput genotyping
capabilities can facilitate pharmacodynamics-based pharmacoge-
netic studies, pharmacoproteomic studies may provide additional
information regarding variability in warfarin dose requirements in
patients. Phenotypic traits are often the result of various proteins
functioning in a concerted manner post-translationally and may be
important in influencing interindividual variations to warfarin
treatment [11]. The field of pharmacoproteomics may be more
important than the pharmacogenetics of individual patients as it
represents the effects of post-translational modifications of
functional proteins which are responsible for the phenotypic
effects and may serve as important biomarkers in patients. The
objective of this exploratory study was to investigate the proteomic
profile of patients receiving low- and high-dose warfarin and to
perform correlative studies between genotypic and proteomic
markers in the two groups of patients.
Methods
Patient’s blood and tissue samples
The plasma proteomic profile of 53 patients (25 on low- and 28
on high-dose warfarin therapy) were analyzed in the present pilot
study. These patients were part of a larger cohort of patients that
participated in a previously reported study [24]. All human
participants selected in this study have been approved by
Singapore General Hospital Ethics Committee. Written informed
consent has been obtained and all clinical investigations have been
conducted according to the principles expressed in the Declaration
of Helsinki. All patients were required to be on a stable
maintenance dose of warfarin for at least one month with their
international normalized ratio (INR) maintained between 2.0 and
3.0, and had no bleeding episodes. Patients with congestive heart
failure (NYHA class 3 or greater), liver cirrhosis, thyroid disease or
chronic gastrointestinal conditions were excluded from the study.
Patients taking concurrent medications with potential to interact
with warfarin included simvastatin (n=15) and omeprazole
(n=18).
Healthy, non-cancerous liver tissues certified to be of malig-
nancy free by pathologic examinations (n=36) (from Chinese
cancer patients undergoing hepatectomy for metastasis from a
colonic primary malignancy) were available for the present
genotyping and gene expression studies. All patients provided
approved informed consent for participating in the study, and
permission was also obtained from the institution’s Ethics
Committee.
Pharmacogenetic analysis of VKORC1 polymorphic
variants
The pharmacogenetics of VKORC1 [381T.C(rs7196161),
861C.A(rs17880887), 3673G.A(rs9923231), 5808T.G(rs2884
737), 6484C.T(rs9934438), 6853C.G(rs8050984), 7566C.T
(rs2359612) and 9041G.A(rs7294)] were determined in 53
patients receiving warfarin. The genotyping procedures were in
accordance to recently published studies by our group [23,24].
Protein preparation and iTRAQ labeling
Protein from plasma samples was prepared in accordance to our
previously published methodology [25]. Briefly, samples were
centrifuged and the supernatant was stored. The protein levels
were quantified using the 2-D Quant Kit (GE Healthcare). Each
sample (100 mg) was precipitated by the addition of 4 volumes of
cold acetone, dissolved in the solution buffer, denatured and
cysteines blocked as described in the iTRAQ (Isobaric tags for
relative and absolute quantitation) protocol (Applied Biosystems).
All samples were analyzed in three independent analyses.
2-D Nano-LC-MS/MS analysis and data interpretation
In the first step of the separation, 3 ml of the combined
peptide mixture were loaded onto the PolySulfoethyl A strong
cation exchange column (SCX) (0.32650 mm, 5 mm) [26]. The
flow-through with peptides that do not bind to the SCX column
is trapped in the Zorbax 300SB-C18 enrichment column and
washed isocratically to remove excess reagent. In the second
step, this enrichment column was switched into the solvent path
of the nanopump and the peptides were eluted. An increasing
concentration of acetonitrile elutes the concentrated sample and
further separation was achieved onto the analytical Zorbax
300SB-C18 reversed-phase column. For electrospray analysis,
the HP1200 LC system (Agilent Technologies) was interfaced to
a QSTAR XL (Applied Biosystems-MDS Sciex) mass spectrom-
etry. After the first analysis was completed, the enrichment
column was switched again into the solvent path of the cation
exchange column. Peptide identifications and quantization was
performed using Proteinpilot software packages (Applied Bio-
systems). Each MS/MS spectrum was blasted against the human
protein database and protein identifications were accepted based
on Proteinpilot confidence scores, which are based on peptide
scores, number of peptides and distance from nearest neighbor
[26,27]. Relative quantification of proteins in the case of
iTRAQ was performed on the MS/MS scans and is the ratio
of the areas under the peaks at 114, 115, 116, and 117 Da which
represents the masses of the tags that correspond to the iTRAQ
reagents.
Total and free T3 and T4 immunoassay
The plasma samples of the patients (n=53) were quantitated for
the major thyroid hormones. Plasma levels of triiodothyronine (T3)
and thyroxine (T4) (both total and free) were determined by
chemiluminescent immunoassay using UniCel
TM DxI 800 Ac-
cessH Immunoassay System (Beckman Coulter, Fullerton, CA,
USA) at the Department of Biochemistry, Singapore General
Hospital as per the manufacturer’s protocol. In brief, free
triiodothyronine (FT3) and thyroxine (FT4) were determined by
immunocapture and competitive-binding procedure while total
triiodothyronine (TT3) and thyroxine (TT4) were measured in a
one-step competitive-binding procedure. Reference intervals for
the above assays were FT3 (3.2–5.3 pmol/L), FT4 (8.8–
14.4 pmol/L), TT3 (1.1–2.6 nmol/L) and TT4 (74–144 nmol/L).
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Total RNA was isolated from human liver samples (n=36)
using RNeasy Mini Kit (Qiagen). The amount and purity of the
extracted total RNA was assessed in ND-1000 spectrophotometer
by employing a module of extinction coefficient 40 to assess
acceptable ratio of 260/280 ,2.0 and 260/230 ratio range of 1.8–
2.2. Prior to cDNA synthesis, total RNA (5 mg) from each sample
was subjected to DNase treatment using TURBO DNA–free
TM
(Ambion) to eliminate trace levels of genomic DNA contamina-
tion. After DNase treatment, 1 mg of total RNA was reverse-
transcribed using high-capacity cDNA reverse transcription kits
(Applied Biosystems) according to the manufacturer’s procedure.
A2mL of cDNA sample was used as a template (i.e., 100 ng) to
study the expression of TTR using TaqMan gene expression assay
Hs00174914_m1 (Applied Biosystems). The reactions, in 20 mL,
were performed in 7500 Fast Real-Time PCR systems (Applied
Biosystems) as per the manufacturer’s protocol. Constitutively
expressed b–actin mRNA was simultaneously assayed by TaqMan
human b–actin assay (part no.: 4333762F; Applied Biosystems) as
an internal standard for sample normalization. All experiments
were repeated three times, in triplicate. The expression of the TTR
mRNA was calculated using the 2
-DCT method as described by
Livak and Schmittge (2001).
HepG2 cell culture and warfarin exposure regimen
Human liver hepatoma cells (HepG2 cells) obtained from
American Type Culture Collection (ATCC) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented in
10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium
pyruvate, and antibiotics penicillin (100 units/mL) and strepto-
mycin (100 mg/mL). The cells seeded at ,10
5 cells/mL were
maintained in 75-cm
2 flasks at 37uC in a humidified 5% CO2
incubator with medium change every 3 days. Subcultures of cells
were carried out from a 1:4 split of 80–90% confluent monolayer
using 0.125% Trypsin-EDTA solution. Under the same culture
conditions, the HepG2 cells cultured in the DMEM without FBS
are referred to as serum-minus HepG2 cells.
Warfarin stock prepared in methanol (95%) was used in culture
medium to obtain the following final warfarin concentrations: 1.0
and 10 mg/ml (at ,0.5% methanol). Twenty four hours before the
cells were used in the experiments, the cells were sub-cultured at
2610
6 cells/mL in 25-cm
2 flasks with fresh culture medium. At the
start of the experiment, culture medium was removed and the
monolayer was gently washed 2 times with pre-warmed (37uC)
phosphate buffer saline (PBS, pH 7.3), and cells were then
incubated in FBS-plus or FBS-minus DMEM containing warfarin
to obtain the above final concentrations. The experimented cells
(FBS-plus and FBS-minus) were harvested by scrapping out the
cells at: 24 hrs (n=3; flasks/concentration/time point). The
scraped cells were transferred into 15 mL conical tubes by
addition of 2 ml of cold PBS (5uC), and were pelleted immediately
by centrifuging at 1206g for 10 min at 4uC. The harvested cell
pellets were frozen immediately at 280uC for future experiments.
Western immunoblotting
Total Protein from healthy hepatic tissues and warfarin exposed
HepG2 cells were extracted using the Trizol method (Invitrogen)
as per the manufacturer’s protocol. Protein samples which are
dissolved in 1% SDS were quantified using Bio-Rad DC Protein
Assay. A measure of 200 mg protein is loaded per well to 12%
SDS-PAGE gel. The proteins are transferred to Immobilon
TM
PVDF Transfer Membranes (0.45 mm) using Bio-Rad Criterion
Cell. After transfer, membrane is incubated with 5% (w/v) non-fat
dried milk (Bio-Rad) in PBS/T, which is used as the blocking
buffer after transfer, for one hour at room temperature. After
blocking, the membrane is incubated with Rabbit polyclonal
Prealbumin antibody from abcamH (ab16006) which is diluted in
PBS/T (1:3000) at 4uC placed on a rocker. Next day, the
membrane is washed with PBS/T for 10 minute each for three
times and incubated with Goat Anti-Rabbit Ig HRP Conjugate
(Sigma-AldrichH) diluted in 5% non-fat dried milk PBS/T (1:7500)
at room temperature for one hour. Membrane is washed three
times at 10 min interval with wash buffer (PBS/T). Bands are
developed in CL-XPosure Film from pierce using Super signal
West Pico Chemiluminescent Substrate. For endogenous loading
control, we used Anti-GAPDH antibody produced in rabbit from
Sigma-AldrichH (G9545). TTR expression was then normalized
against the endogenous control using the Multi Gauge Ver. 3.0
Software (FUJI FILM).
OptEIA
TM human IL-6 ELISA
IL-6 concentrations in plasma samples (low-dose warfarin,
N=39; high-dose warfarin, N=37) were determined in duplicate
by OptEIA
TM ELISA (BD Biosciences, San Jose, U.S.A) in
accordance with the manufacturer’s protocol. The assay utilized a
human monoclonal antibody specific to IL-6 and biotinylated anti-
human IL-6 monoclonal antibody mixed with streptavidin-
horseradish peroxidase conjugate for detection at 450 nm. The
minimal detection sensitivity of the assay was 2.2 pg/mL and
intra- and inter-assay coefficients of variation were 4.1 to 10.8, and
7.9 to 10.9, respectively. In order to acquire minimal baseline
(2.2 pg/mL) for all the plasma samples, the initial additions of
ELISA diluent (i.e., 50 mL/well) were spiked with the standard IL-
6 to the concentration 3.0 pg/mL. An appropriate internal control
was maintained in each assay to correct for the spiked base line for
absolute IL-6 quantification. The absorbance of the IL-6 standards
were fit by linear regression (R
2=0.99) and the amount of IL-6 in
the samples was quantified on the basis of this equation.
Statistical analysis
The non-parametric Mann-Whitney U test and Kruskal-Wallis
test were used to assess differences in VKORC1 diplotype classes
and warfarin dose levels association with different parameters
TTR, thyroid hormones and IL-6. The level of significance was set
as P,0.05 for all comparisons. All statistical analyses were
performed using SPSS 16.0 (SPSS, Chicago, IL, USA).
Results
Patient demographics
Approximately 70% of the patients were males and the median
age of the patients were 63 years (range: 46 to 75 years) and 50
years (range: 29 to 81 years) in the low- and high-dose warfarin
groups, respectively. The median warfarin dose in patients
receiving low-dose warfarin was 2.5-fold lower compared to
patients receiving high-dose warfarin [low-dose versus high dose:
2.5 mg (range: 1 mg to 3.5 mg) vs 6.25 mg (range: 4.5 mg to
10.5 mg)]. Indications for warfarin therapy included deep vein
thrombosis (44%) and cardiovascular conditions (atrial fibrillation,
mitral valve regurgitation, transient ischaemic attack and stroke),
(56%).
Pharmacogenetics of VKORC1
The genotype frequencies of VKORC1 polymorphic variants
were in Hardy-Weinberg equilibrium. The distribution of
VKORC1 diplotypes frequencies is summarized in Table 1. The
majority of the patients in the low dose warfarin group carried the
VKORC1 H1H1 genotype (N=23; 92%) while H1H7 diplotype
Transthyretin Precursor and Warfarin Therapy
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50%). VKORC1 diplotype data were not available in two patients.
Proteins identified by iTRAQ-coupled 2D LC-MS/MS
The proteomic profiles of patients receiving low- and high-dose
warfarin therapy were investigated using iTRAQ-coupled 2D LC-
MS/MS which was recently applied in the analysis of cellular
protein profile in response to incubation with various chiral drugs,
such as propranolol, ibuprofen and atenolol [25,26,27]. A total of
163 proteins were identified by iTRAQ-coupled LCMS/MS
analysis. Identification of protein with significant expression level
was based on the ProtScore with the cut-off at 2.0 and a
confidence value of 99%. A total of 11 proteins satisfied these
criteria and the results were reproducible when repeated in
triplicates. As shown in Figure 1, of the differential proteins that
were detected, the expression levels of TTR precursor was found
to be significantly different between the patients requiring low-
and high warfarin dose (P,0.0001).
Influence of VKORC1 diplotypes on TTR levels
Figure 2 illustrates the influence of VKORC1 diplotypes on
transthyretin precursor levels. Patients harboring the H1H1
diplotype displayed significantly higher levels of the transthyretin
precursor compared to patients harboring the H7H7 or H7/H8/
H9 diplotypes, which were associated with high warfarin dose
requirement (H1H1 vs. H7H7 vs. H7/H8/H9: values, P,0.0001).
Influence of VKORC1 diplotypes on thyroid T3 and T4
levels
The free and bound T3 and T4 levels were within the normal
physiological range in all patients The median levels of FT3,F T 4,
Table 1. The distribution of VKORC1 diplotypes in patients
receiving low-dose (N=25) and high-dose (N=28) warfarin.
VKORC1 H1H1 H1H7 H1H9 H7H7 H7H8H9 Missing TOTAL
Low Dose 23 2 0 0 0 0 25
High Dose 1 14 2 6 3 2 28
doi:10.1371/journal.pone.0015064.t001
Figure 1. Differential expression of plasma protein levels in patients treated at low- and high-dose warfarin identified by iTRAQ-
coupled LC-MS/MS analysis. A total of 163 proteins were identified and 11 proteins with significant expression levels were identified based on
ProtScore with a cut-off value of 2.0 at 99% confidence value. Of the eleven proteins, the median expression level of transthyretin precursor was
highly significant between patients receiving low- and high-dose warfarin group (low-dose: 1.53, range: 0.828 to 3.83; and high-dose: 0.818, range:
0.534 to 1.483; P,0.0001).
doi:10.1371/journal.pone.0015064.g001
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12.6 pmol/L (range: 9.8–19.6 pmol/L), 1.3 nmol/L (0.9–
2.1 nmol/L) 101 nmol/L (range: 45–158 nmol/L) respectively
in the low dose warfarin group (n-25) and 4.7 pmol/L (range: 2.5–
6.8 pmol/L), 12.6 pmol/L (range: 9–17.7 pmol/L), 1.5 nmol/L
(0.9–2.3 nmol/L) and 98 nmol/L (range: 58–139 nmol/L), re-
spectively in the high dose warfarin group (n=28). Figure 3A, B, C
and D depicts the influence of VKORC1 diplotypes on plasma FT3,
FT4,T T 3 and TT4 hormone levels. Significant differences were
noted for FT3 and TT3 between patients harbouring H1H1 and
H1H7/H1H9 diplotypes (Figure 4A and B, respectively) but not
between patients carrying the high dose diplotypic groups (H1H7/
H1H9 and H7H7/H7H8H9). The effect of VKORC1 diplotypes
on FT4 and TT4 were non-significant.
TTR mRNA expression in hepatic tissues
The impact of VKORC1 diplotypes, H1H1, H1H7and H7H7, on
the hepatic mRNA expression of TTR was investigated in 33
healthy hepatic tissue samples. The median TTR mRNA expression
levels were shown to be similar (P=0.88) across different VKORC1
diplotypes (data not shown). The median (range) TTR mRNA
expression level in hepatic tissues harboring H1H1 diplotype
[259.16 (18.31–2691.12)] was comparable to that of hepatic tissues
harboring H1H7/H7H7 diplotypes [273.71 (35.83–1023.66)]. We
further evaluated the influence of VKORC1 diplotypes on protein
expression of TTR (data not shown). Similar to the TTR mRNA
expression, the GAPDH normalized ratios of TTR protein
expression levels were not found to be significantly different
between hepatic tissues harboring different VKORC1 diplotypes.
TTR protein expression in HepG2 cells
In order to explain the negative correlation between the dose
dependent warfarin treatment and TTR expression, we carried
out an in vitro experiment using HepG2 cells which were exposed
to low (1.0 mg/ml) and high (10 mg/ml) dose warfarin treatment
for 24 hrs (with or without serum). Compared with control (0 hr),
an average of 2.3 fold difference in the TTR protein expression
was observed in cells exposed to low and high dose warfarin at
24 hrs (Figure 4A and B).
IL-6 quantification of low- and high-dose warfarin
patients
Interleukin-6 is an inflammatory cytokine and its secretion has
been previously shown to vary according to warfarin levels[28,29].
We thus sought to investigate the IL-6 levels in plasma samples of
patients receiving low- and high-dose warfarin (Figure 5). The
median IL-6 concentrations were 3.3 pg/mL (range: 0.14–
19.05 pg/mL) and 4.4 pg/mL (range: 1.4–117.16 pg/mL), re-
spectively in the low-dose and high-dose warfarin (P=0.018).
Discussion
The field of pharmacoproteomics is fast expanding and is
proving to be a useful adjunct to pharmacogenetics and
Figure 2. Influence of VKORC1 diplotypes on TTR precursor level in warfarin treated Asian patients (N=51). Patients carrying the H1H1
diplotype showed significantly higher levels of TTR precursor compared to patients harboring the H1H7/H1H9 (P=0.001) and H7H7/H7H8H9
diplotypes (P,0.0001).
doi:10.1371/journal.pone.0015064.g002
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and toxicology studies. In addition to pharmacogenetic factors,
pharmacoproteomic profiling in patients has several associated
advantages with regards to personalized drug therapy: firstly, it is
directly associated with the observed phenotypic changes following
drug therapy and secondly, it provides a better representation of
the true nature of interpatient variations that are often observed
between patients. The objective of the present exploratory study
was to investigate for warfarin-specific biomarkers by performing
collective genetic and proteomic profiling in patients who had
received low- and high-dose warfarin.
Our study on plasma protein profiling showed that TTR
precursor (54,980 Da.) was differentially expressed in patients who
received low- and high-dose warfarin. Patients receiving low-dose
warfarin were found to express higher TTR protein in plasma
than patients in the high-dose group (Figure 1; P,0.0001). In
addition, an inverse relationship was observed between VKORC1
diplotype status and TTR levels in this exploratory study. Patients
carrying the H1H1 diplotype displayed higher expression of TTR
precursor whereas those carrying the H1H7/H1H9 diplotype
showed lower expression of TTR precursor (Figure 2). We had
previously established that VKORC1 mRNA is differentially
expressed in hepatic tissues, with lower levels in patients carrying
the H1H1 diplotype and higher levels in patients carrying the
H1H7 diplotype[30]. To investigate if a similar relationship was
inherent between hepatic VKORC1 and TTR mRNA expression,
real-time PCR and protein immunoblot analysis were carried out.
Both analyses revealed absence of any significant difference in
TTR mRNA and protein levels between the different VKORC1
genotypic groups.
TTR is predominantly produced in the liver and circulating
TTR in plasma has approximately 100-fold lower affinity for
thyroid hormones compared with thyroid binding globulin
(TBG). Approximately 0.5% of circulating TTR is involved in
the secondary transport of thyroid hormones T3 and T4 while a
major portion exists in bound form to retinol binding
protein[31,32,33]. A recent estimate revealed that most of the
circulating TTR (0.15–0.3 mg/ml; 3–6 mM) is present in the
unbound form and may possess multiple undiscovered biolog-
ical functions[34]. Accordingly, changes in plasma TTR
concentrations will be expected to have relatively little ef-
fect on the serum concentrations of thyroid hormones[33].
Figure 3. Effect of VKORC1 diplotypes [H1H1 (n=24), H1H7/H1H9 (n=18) and H7H7/H7H8H9 (n=9)] on (A) free T3 (FT3), (B) total T3
(TT3), (C) free T4 (FT4), and (D) total T4 (TT4) levels in patients receiving warfarin. Patients harboring the H1H1 diplotype group had
significantly lower FT3 and TT3 levels compared with patients carrying the high dose (H1H7/H1H9) associated diplotype groups (Figures 3A and B;
P,0.05 in each case). These findings probably reflect the higher levels of TTR expressed in patients carrying the low dose H1H1 diplotype, which
probably leads to lower levels of FT3 as well as TT3.
doi:10.1371/journal.pone.0015064.g003
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and TT3 levels between patients carrying the low-dose (H1H1)
and high-dose (H1H7/H1H9) associated diplotype groups
(Figure 3A and B), the plasma levels of these hormones were
within the normal biochemical range. These findings suggest
that the influence of warfarin on plasma TTR levels is
independent of the latter’s negligible influence on circulating
thyroid hormone levels and are therefore unlikely to affect
physiological functions.
We next investigated in an in vitro model if the differential
expression levels of TTR were due to warfarin treatment effect.
HepG2 cells cultured under serum-minus as well as serum-plus
conditions and exposed to low (1.0 mg/ml) and high (10 mg/ml)
warfarin concentrations for 24 hrs showed the TTR expression
patterns were inversely proportional to warfarin dosage (Figure 4A
and B). Immunoblot analysis also revealed higher levels of TTR
expression in cell culture system exposed to low concentrations of
warfarin compared with those exposed to high concentrations of
Figure 4. Immunoblot expressions of TTR levels in HepG2 cells exposed to low (1.0 mg/mL) and high (10 ug/mL) concentrations of
warfarin for 24 hrs. TTR expression levels were determined in (A) serum-rich, and (B) serum-free conditions to exclude the possibility of false
positive results. The data (mean 6 S.E.) represents expression ratios of biological replicates normalized to GAPDH. The decrease in expression of TTR
was significantly greater in HepG2 cells exposed to higher concentration (10 ug/mL) of warfarin under serum-rich conditions (Fig. 4A; P=0.01).
doi:10.1371/journal.pone.0015064.g004
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warfarin concentrations, the experiments were conducted under
serum-minus and serum-plus conditions. In a parallel study,
warfarin showed negligible binding to TTR when studied using
RP-HPLC as opposed to its being almost 100% bound with
human albumin (data not shown). These findings suggest that
warfarin may induce TTR expression in a dose-dependent
manner. Further studies are required to validate these findings.
Increased IL-6 has been previously shown to decrease the
transcription and translation of TTR in HepG2 cells[28,35]. Also,
low-dose warfarin has previously been reported to exert an anti-
inflammatory effect through the suppression of IL-6 activity. In
contrast, high-dose warfarin tends to activate pro-inflammatory
signaling via increased IL-6 production[29,36,37]. In our study,
concomitant with earlier findings, patients receiving high dose
warfarin showed significantly increased levels of IL-6 in compar-
ison with those receiving low-dose warfarin (Figure 5; p,0.05).
The exact mechanism for this observation is not known. Kater et
al[29] had previously reported similar findings and suggested that
warfarin exerts its anti-inflammatory actions by affecting the
phosphorylation of I-kB. Further studies are required to elucidate
the mechanism underlying these observations.
In summary, this study showed that variations in TTR levels
were associated with specific dosing regimens of warfarin. In
addition to pharmacogenomic biomarkers currently being em-
ployed as an aid in the dosing of warfarin, pharmacoproteomic
biomarkers such as TTR should also be tested in warfarin dosing
algorithms. Future studies should investigate if the inclusion of
both pharmacogenetic and pharmacoproteomic biomarkers may
contribute to further improvement in variations of warfarin dose
requirements.
Author Contributions
Conceived and designed the experiments: WNC BC. Performed the
experiments: GMK JB LS GMK OS KS. Analyzed the data: CBC WNC
BC. Contributed reagents/materials/analysis tools: GMK JB LS GMK OS
KS. Wrote the paper: WNC CBC.
References
1. Anand SS, Yusuf S (1999) Oral anticoagulant therapy in patients with coronary
artery disease: A meta-analysis. Journal of the American Medical Association
282: 2058–2067.
2. Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and
reinfarction after myocardial infarction. New England Journal of Medicine 323:
147–152.
3. Beyth RJ, Milligan PE, Gage BF (2002) Risk factors for bleeding in patients
taking coumarins. Current hematology reports 1: 41–49.
4. Wells PS, Holbrook AM, Crowther NR, Hirsh J (1994) Interactions of warfarin
with drugs and food. Annals of Internal Medicine 121: 676–683.
5. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, et al. (2004)
Contribution of age, body size, and CYP2C9 genotype to anticoagulant
response to warfarin. Clinical Pharmacology and Therapeutics 75: 204–
212.
6. Absher RK, Moore ME, Parker MH, Rivera-Miranda G, Perreault MM (2002)
Patient-specific factors predictive of warfarin dosage requirements. Annals of
Pharmacotherapy 36: 1512–1517.
7. Gan GG, Teh A, Goh KY, Chong HT, Pang KW (2003) Racial background is a
determinant factor in the maintenance dosage of warfarin. International Journal
of Hematology 78: 84–86.
8. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, et al. (2002) Influence of
CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose
and metabolic clearance. Clinical Pharmacology and Therapeutics 72: 702–
710.
Figure 5. OptEIA
TM quantification of IL-6 from low- and high-dose warfarin treated patients. Box plot shows the median IL-6
concentrations of low-dose (3.3 pg/mL; range: 0.14 to 19.05 pg/mL) and high-dose (4.4 pg/mL; range: 1.4 to 117.16 pg/mL) warfarin treated groups.
Patients on high-dose warfarin (N=37) showed significantly increased levels of IL-6 in comparison with those on low-dose (N=39) warfarin
[P=0.018].
doi:10.1371/journal.pone.0015064.g005
Transthyretin Precursor and Warfarin Therapy
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e150649. Liu L, Liu J, Dai S, Wang X, Wu S, et al. (2007) Reduced transthyretin
expression in sera of lung cancer. Cancer Science 98: 1617–1624.
10. Limdi NA, Veenstra DL (2008) Warfarin pharmacogenetics. Pharmacotherapy
28: 1084–1097.
11. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annual Review of Med-
icine 63–75.
12. Breckenridge A, Orme M, Wesseling H (1974) Pharmacokinetics and
pharmacodynamics of the enantiomers of warfarin in man. Clinical Pharma-
cology and Therapeutics 15: 424–430.
13. Takahashi H, Echizen H (2001) Pharmacogenetics of warfarin elimination and
its clinical implications. Clinical Pharmacokinetics 40: 587–603.
14. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms:
A comprehensive review of the in-vitro and human data. Pharmacogenetics 12:
251–263.
15. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, et al. (2001) Genetic
polymorphism of cytochrome P450 2C9 in a Caucasian and a black African
population. British Journal of Clinical Pharmacology 52: 447–450.
16. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, et al. (2001) Frequency of
cytochrome P450 2C9 mutant alleles in a Korean population. British Journal of
Clinical Pharmacology 51: 277–280.
17. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, et al. (2004) Novel CYP2C9
genetic variants in Asian subjects and their influence on maintenance warfarin
dose. Clinical Pharmacology and Therapeutics 76: 210–219.
18. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9
polymorphisms on warfarin sensitivity and risk of over-anticoagulation in
patients on long-term treatment. Blood 96: 1816–1819.
19. Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of
polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose
requirement and risk of bleeding complications. Lancet 353: 717–719.
20. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, et al. (2004) Identification of the
gene for vitamin K epoxide reductase. Nature 427: 541–544.
21. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, HA ˜"rtnagel K, et al. (2004)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation
factor deficiency type 2. Nature 427: 537–541.
22. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of
VKORC1 haplotypes on transcriptional regulation and warfarin dose. New
England Journal of Medicine 352: 2285–2293.
23. Sandanaraj E, Lal S, Cheung YB, Xiang X, Kong MC, et al. (2009) VKORC1
diplotype-derived dosing model to explain variability in warfarin dose
requirements in Asian patients. Drug Metabolism and Pharmacokinetics 24:
365–375.
24. Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, et al. (2008) Influence of
APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in
Asian patients. British Journal of Clinical Pharmacology 65: 260–264.
25. Sui J, Zhang J, Tan TL, Ching CB, Chen WN (2008) Comparative proteomics
analysis of vascular smooth muscle cells incubated with S- and R-Enantiomers of
atenolol using iTRAQ-coupled two-dimensional LC-MS/MS. Molecular and
Cellular Proteomics 7: 1007–1018.
26. Sui J, Tuan LT, Zhang J, Chi BC, Wei NC (2007) iTRAQ-coupled 2D LC-MS/
MS analysis on protein profile in vascular smooth muscle cells incubated with S-
and R-enantiomers of propranolol: possible role of metabolic enzymes involved
in cellular anabolism and antioxidant activity. Journal of Proteome Research 6:
1643–1651.
27. Zhang J, Sui J, Chi BC, Wei NC (2008) Protein profile in neuroblastoma cells
incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-
MS/MS analysis: Possible action of induced proteins on Alzheimer’s disease.
Proteomics 8: 1595–1607.
28. Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, et al. (1997) Interleukin-
6 downregulates factor XII production by human hepatoma cell line (HepG2).
Blood 90: 1501–1507.
29. Kater AP, Peppelenbosch MP, Brandjes DPM, Lumbantobing M (2002)
Dichotomal effect of the coumadin derivative warfarin on inflammatory signal
transduction. Clinical and Diagnostic Laboratory Immunology 9: 1396–1397.
30. Sandanaraj E, Lal S, Cheung YB, Xiang XQ, Kong MC, et al. (2009)
VKORC1 Diplotype-Derived Dosing Model to Explain Variability in Warfarin
Dose Requirements in Asian Patients. Drug Metabolism and Pharmacokinetics
24: 365–375.
31. Purkey HE, Dorrell MI, Kelly JW (2001) Evaluating the binding selectivity of
transthyretin amyloid fibril inhibitors in blood plasma. Proceedings of the
National Academy of Sciences of the United States of America 98: 5566–5571.
32. Palha JA (2002) Transthyretin as a thyroid hormone carrier: Function revisited.
Clinical Chemistry and Laboratory Medicine 40: 1292–1300.
33. Feldt-Rasmussen U, Rasmussen AK (2007) Thyroid hormone transport and
actions; Krassas GE, Rivkees SA, Kiess W, eds. Basel: Karger.
34. Buxbaum JN, Reixach N (2009) Transthyretin: the servant of many masters.
Cellular and Molecular Life Sciences 66: 3095–3101.
35. Bartalena L, Farsetti A, Flink IL, Robbins J (1992) Effects of interleukin-6 on the
expression of thyroid hormone-binding protein genes in cultured human
hepatoblastoma-derived (Hep G2) cells. Molecular Endocrinology 6: 935–942.
36. Maclean PS, Tait RC, Rumley A, McMahon AD, Lowe GD (2003)
Anticoagulation with warfarin downregulates inflammation. Journal of Throm-
bosis and Haemostasis 1: 1838–1839.
37. Kurohara M, Yasuda H, Moriyama H, Nakayama M, Sakata M, et al. (2008)
Low-dose Warfarin Functions as an Immunomodulator to Prevent Cyclophos-
phamide-induced NOD Diabetes. Kobe J Med Sci 51: E1–E13.
Transthyretin Precursor and Warfarin Therapy
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e15064